Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Investment analysts at Leerink Swann lowered their FY2018 earnings per share estimates for shares of Amicus Therapeutics in a research report issued to clients and investors on Monday, November 5th. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($1.20) for the year, down from their prior forecast of ($1.12). Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2018 earnings at ($0.27) EPS, Q1 2019 earnings at ($0.25) EPS, Q2 2019 earnings at ($0.24) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.24) EPS, FY2019 earnings at ($0.96) EPS and FY2020 earnings at ($0.83) EPS.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $20.60 million for the quarter, compared to analysts’ expectations of $23.56 million. Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. Amicus Therapeutics’s revenue was up 89.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.41) EPS.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. BidaskClub cut shares of Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 18th. Chardan Capital cut shares of Amicus Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $18.00 to $15.00 in a research note on Friday, August 17th. Cowen reaffirmed a “buy” rating and set a $31.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 12th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $19.50.

Shares of NASDAQ:FOLD opened at $11.41 on Wednesday. The company has a market cap of $2.24 billion, a P/E ratio of -3.91 and a beta of 1.48. Amicus Therapeutics has a 12 month low of $10.33 and a 12 month high of $17.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 10.88 and a quick ratio of 10.73.

A number of hedge funds have recently added to or reduced their stakes in FOLD. Exane Derivatives bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth approximately $137,000. P.R. Herzig & Co. Inc. bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $156,000. Arbor Wealth Management LLC bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $144,000. Quantitative Systematic Strategies LLC bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $179,000. Finally, TCW Group Inc. bought a new stake in Amicus Therapeutics during the 2nd quarter valued at $245,000.

In related news, major shareholder Life Sciences Maste Perceptive purchased 50,000 shares of the business’s stock in a transaction on Wednesday, October 3rd. The stock was acquired at an average price of $12.59 per share, with a total value of $629,500.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $12.23, for a total transaction of $122,300.00. Following the completion of the transaction, the chief financial officer now directly owns 127,622 shares of the company’s stock, valued at approximately $1,560,817.06. The disclosure for this sale can be found here. In the last three months, insiders acquired 620,000 shares of company stock valued at $7,505,000. Corporate insiders own 2.90% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

See Also: Understanding the different types of bonds

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.